{"prompt": "['7', 'Intercurrent events', '7.1 Definitions', '7.1.1 Adverse event', 'An adverse event (AE) is any untoward medical occurrence in a patient or clinical', 'investigation patient administered a pharmaceutical product and which does not', 'necessarily have to have a causal relationship with this treatment.', 'An adverse event can therefore be any unfavourable and unintended sign (including', 'an abnormal laboratory finding, for example), symptom, or disease temporally', 'associated with the use of a medicinal product, whether or not considered related to', 'the medicinal product.', '7.1.2 Serious adverse event (SAE)', 'A serious adverse event (SAE) is any untoward medical occurrence that at any dose:', 'Results in death', 'Is life-threatening (the term \"life-threatening\" in the definition of \"serious\" refers', 'to an event in which the patient was at risk of death at the time of the event ; it', 'does not refer to an event which hypothetically might have caused death if it', 'were more severe)', 'Requires in-patient hospitalization or prolongation of existing hospitalization', 'Results in persistent or significant disability/incapacity', 'Is a congenital anomaly/birth defect', 'Is a medically significant event:', 'Medical and scientific judgment should be exercised in deciding whether expedited', 'reporting is appropriated in situations, such as important medical events that may not', 'be immediately life-threatening or result in death or hospitalization but may jeopardize', 'the patient or may require intervention to prevent one of the outcomes listed in the', 'definition above.', 'The term \"severe\" is a measure of intensity, thus a severe adverse event is not', 'necessarily serious. For example, \"nausea of several hours\" duration may be severe', 'but may not be clinically serious.', 'For \"TACRO\" study, any tacrolimus blood concentration resulting > 5ng/ml and', 'any sign of infection under treatment should be considered as medically', 'significant event and reported immediately by the investigator to the sponsor as', 'a SAE.', '7.1.3 Intensity', 'The intensity of the event will be graded according to the following classification:', 'Mild (grade 1): Discomfort noticed but no disruption of normal daily activity', 'Moderate (grade 2): Discomfort sufficient to reduce or affect normal daily', 'activity', 'Severe (grade 3): Incapacitating with inability to work or perform normal daily', 'activity', 'Life-threatening (grade 4): Substantial risk of dying at time of event', 'Death: (grade 5)', 'Page 43 of 64']['7.1.4 Adverse reaction', 'An adverse reaction implies at least a reasonable possibility of a causal relationship', 'between a suspected medicinal product and an adverse event. An adverse reaction,', 'in contrast to an adverse event, is characterised by the fact that a causal relationship', 'between a medicinal product and an occurrence is suspected.', '7.1.5 Reference document for the experimental drug', 'Reference document for the experimental drug n\u00b01: Summary of Product', 'Characteristics (SPC) for PROTOPIC 0.1% (tacrolimus).', '7.2 Responsabilities of the investigator', '7.2.1 Adverse Events reporting', 'All adverse events (AE) regardless of seriousness or relationship to Investigational', 'Product that occurred after the informed consent up to 30 days after the last study', 'drug administration are to be recorded in the AE pages of the Case Report Form', '(CRF). After this delay only fatal AE and adverse event related to the IMP must be', 'recorded.', 'Whenever possible, symptoms should be grouped as a single syndrome or diagnosis.', 'The investigator should specify the date of onset, intensity, action taken regarding trial', 'medication, corrective therapy given, outcome of all adverse events and his opinion as', 'to whether the adverse event can be related to the study drugs and/or to concomitant', 'drugs.', 'All events that meet one or more criteria of seriousness will be reported as Serious', 'Adverse Event.', '7.2.2 General AE/SAE reporting rules:', 'Any episode of any grade of toxicities, related to a Serious Adverse Event must be', 'reported as \"Adverse Event\" in the appropriate CRF pages.', 'Adverse events (serious or not) will not be recorded after the start of a new out-of-', 'study treatment or after disease progression.', 'Planned hospital admissions or surgical procedures for an illness or disease which', 'existed before the patient was enrolled in the study or before study drug was given are', 'not to be considered SAEs unless the condition deteriorated in an unexpected manner', 'during the study (eg surgery was performed earlier than planned).', 'All adverse events which meet grade 3, 4 and 5 criteria must be reported immediately', 'to the sponsor.', '7.2.3 SAE declaration', 'All defined Serious Adverse Events (SAEs) occurred after the informed consent', 'up to 30 days after the last study drug administration, whether or not ascribed to', 'the study, will be recorded in the Serious Adverse Event pages. After this delay only', 'fatal SAE and SAE related to the IMP must be recorded.', 'Serious Adverse Event (serious or not) will not be recorded after the start of a new out-', 'of-study treatment or after disease progression (fatal event excluded)', 'All Serious Adverse Events must also be reported on the Adverse Event page of the', 'CRF.', 'In a case of Serious Adverse event The Investigator must immediately:', 'SEND, by fax, the SAE pages to', 'Page 44 of 64']\n\n###\n\n", "completion": "END"}